FDA backs Lilly Alzheimer’s drug; Pfizer Duchenne gene therapy fails; Talc plaintiffs seek J&J bankruptcy restraining order [The good, the bad, the ugly]

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: 

The good — FDA AdComm backs Eli Lilly Alzheimer’s drug
The bad — Pfizer gene therapy fails phase 3 Duchenne trial
The ugly — Talc plaintiffs seek restraining order on J&J bankruptcy tactic